ATE497775T1 - Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv) - Google Patents

Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)

Info

Publication number
ATE497775T1
ATE497775T1 AT05759733T AT05759733T ATE497775T1 AT E497775 T1 ATE497775 T1 AT E497775T1 AT 05759733 T AT05759733 T AT 05759733T AT 05759733 T AT05759733 T AT 05759733T AT E497775 T1 ATE497775 T1 AT E497775T1
Authority
AT
Austria
Prior art keywords
hcv
cyclosporine
hepatitis
treatment
combination
Prior art date
Application number
AT05759733T
Other languages
English (en)
Inventor
Catherine Cornu-Artis
Guylaine Vachon
Yoko Uryuhara
Kazuo Asakawa
Reinhild Elisabeth Mertes
Shinsyou Yoshiba
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE497775T1 publication Critical patent/ATE497775T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT05759733T 2004-07-14 2005-07-13 Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv) ATE497775T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04016583 2004-07-14
PCT/EP2005/007633 WO2006005610A1 (en) 2004-07-14 2005-07-13 Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv)

Publications (1)

Publication Number Publication Date
ATE497775T1 true ATE497775T1 (de) 2011-02-15

Family

ID=34972493

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05759733T ATE497775T1 (de) 2004-07-14 2005-07-13 Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)

Country Status (15)

Country Link
US (1) US7671017B2 (de)
EP (1) EP1778272B1 (de)
JP (1) JP2008506648A (de)
KR (1) KR20070036175A (de)
CN (1) CN1984671A (de)
AT (1) ATE497775T1 (de)
AU (1) AU2005261868B2 (de)
BR (1) BRPI0513370A (de)
CA (1) CA2573207C (de)
DE (1) DE602005026294D1 (de)
ES (1) ES2359925T3 (de)
MX (1) MX2007000503A (de)
PL (1) PL1778272T3 (de)
RU (1) RU2394589C2 (de)
WO (1) WO2006005610A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603512A2 (de) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Neue cyclosporine
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7361636B2 (en) 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
EP1933859A2 (de) 2005-09-30 2008-06-25 Scynexis, Inc. Verfahren und pharmazeutische zusammensetzungen zur behandlung und prävention von hepatitis-c-infektionen
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US8188052B2 (en) 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
CA2724523A1 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
CN102257159A (zh) * 2008-12-18 2011-11-23 弗·哈夫曼-拉罗切有限公司 用于hcv治疗应答的生物标志物
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
MX2011008000A (es) 2009-01-30 2011-09-15 Enanta Pharm Inc Analogos de ciclosporina para la prevención o tratamiento de la infeccion de hepatitis c.
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
EP2585065A1 (de) 2010-06-24 2013-05-01 Panmed Ltd. Behandlung von hepatitis c-virus-bedingten mit hydroxychloroquin oder einer kombination aus hydroxychloroquin und einem anti-virus-mittel
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
BR112014006314A2 (pt) 2011-10-21 2017-04-11 Abbvie Inc métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
HK1223843A1 (zh) 2013-08-26 2017-08-11 Enanta Pharmaceuticals, Inc. 用於預防或治療丙型肝炎的環孢菌素類似物
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
CN109689063B (zh) 2016-04-28 2026-02-27 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
SK278808B6 (sk) 1990-11-02 1998-03-04 Novartis Ag Cyklosporíny, ich použitie pri príprave liečiva na
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en) 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
EP1372695A2 (de) 2000-10-19 2004-01-02 Fujisawa Pharmaceutical Co., Ltd. Inhibitor von zellschaden
DE10316735A1 (de) * 2002-04-05 2003-11-20 Viromics Gmbh Mittel zur Behandlung von Flaviviridae-Infektionen
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
KR101191833B1 (ko) 2004-10-01 2012-10-16 데비오팜 에스 에이 씨형 간염 감염의 치료용［디-멜라］3-［에트발］4-시클로스포린의 이용 및 상기［디-멜라］3-［에트발］4-시클로스포린으로 구성되는 약학 조성물
CN101076350A (zh) 2004-12-23 2007-11-21 诺瓦提斯公司 用于hcv治疗的组合物

Also Published As

Publication number Publication date
CA2573207A1 (en) 2006-01-19
RU2394589C2 (ru) 2010-07-20
CA2573207C (en) 2013-04-16
MX2007000503A (es) 2007-03-08
KR20070036175A (ko) 2007-04-02
WO2006005610A1 (en) 2006-01-19
US20080138316A1 (en) 2008-06-12
EP1778272B1 (de) 2011-02-09
ES2359925T3 (es) 2011-05-30
RU2007105354A (ru) 2008-09-10
AU2005261868A1 (en) 2006-01-19
DE602005026294D1 (de) 2011-03-24
BRPI0513370A (pt) 2008-05-06
CN1984671A (zh) 2007-06-20
JP2008506648A (ja) 2008-03-06
EP1778272A1 (de) 2007-05-02
AU2005261868B2 (en) 2009-01-15
PL1778272T3 (pl) 2011-07-29
US7671017B2 (en) 2010-03-02

Similar Documents

Publication Publication Date Title
ATE497775T1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
ATE490778T1 (de) Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
EA200700243A1 (ru) Способы лечения гепатита с
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
CY1112116T1 (el) Μεθοδος θεραπειας ασθενων με ηπατιτιδα c
EA200401525A1 (ru) Способы лечения гепатита (варианты )
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
RU2010153688A (ru) Режим дозирования телапревира
ATE412666T1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
EA200401618A1 (ru) Лечение гепатита с в азиатской популяции подкожным введением бета-интерферона
DK1613340T3 (da) Behandling af aspergillus-infektioner med thymosin alfa 1
DE60235955D1 (de) Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
UA90477C2 (ru) Способ лечения гепатита с (варианты)
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
TW200740455A (en) PEG-IFN alpha and ribavirin for HBV treatment
DE60002172D1 (de) Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopenten-1-methanol in hbv
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1778272

Country of ref document: EP